Table 2.
Basic demographics of the participants (n=40).
| Characteristic | Participant, n (%) | |
| Age group (years) | ||
|
|
≤40 | 1 (2) |
|
|
41-65 | 12 (30) |
|
|
65-80 | 15 (38) |
|
|
≥80 | 12 (30) |
| Sex | ||
|
|
Male | 17 (42) |
|
|
Female | 23 (58) |
| Cancer diagnosis | ||
|
|
Lung | 12 (30) |
|
|
Colorectal | 6 (15) |
|
|
Head and neck | 5 (12) |
|
|
Pancreas | 4 (10) |
|
|
Liver | 3 (8) |
|
|
Breast | 2 (5) |
|
|
Prostate | 2 (5) |
|
|
Other | 6 (15) |
| AKPSa score on initial assessment | ||
|
|
≤20 | 12 (30) |
|
|
30-50 | 20 (50) |
|
|
60-70 | 7 (18) |
|
|
≥80 | 1 (2) |
| Follow-up time or survival lengthb | ||
|
|
<7 days | 2 (5) |
|
|
8-30 days | 14 (35) |
|
|
1-2 months | 15 (38) |
|
|
2-3 months | 5 (12) |
|
|
>3 months | 4 (10) |
| Wearable device use (%) | ||
|
|
<25 | 3 (8) |
|
|
25-50 | 3 (8) |
|
|
50-75 | 6 (15) |
|
|
75-90 | 9 (22) |
|
|
>90 | 19 (48) |
| Mortality during follow-up timeb | 38 (95) | |
| Participants whose wearable device data were collected until at least 7 days before their death events | 28 (70) | |
aAKPS: Australia-modified Karnofsky Performance Status.
bOverall, 2 (5%) patients left the study for personal reasons. Most patients were followed until their death, for whom the follow-up time represented their survival period.